Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Humasis Co's earnings before interest and taxes (EBIT) for the
three
months ended in Jun. 2026 was ₩-17,572 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was ₩-25,554 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Humasis Co's annualizedROC % for the quarter that ended in Jun. 2026 was -5.71%.
Humasis Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -106.89%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Humasis Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 47.04%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humasis Co EBIT Related Terms
Humasis Co EBIT Historical Data
* Premium members only.
The historical data trend for Humasis Co's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Humasis Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Humasis Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Humasis Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Humasis Co's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-25,554 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humasis Co (XKRX:205470) has a EBIT of ₩-25,554 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Humasis Co.
Is Humasis Co's EBIT too high?
Humasis Co's current EBIT is ₩-25,554 Mil. Overall, Humasis Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Humasis Co's EBIT compare to ABT and SYK?
Humasis Co's EBIT of ₩-25,554 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Humasis Co. Humasis Co's current EBIT is ₩-25,554 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humasis Co stock overvalued right now?
Based on GuruFocus' analysis, Humasis Co (XKRX:205470) is currently considered Possible Value Trap. The stock's GF Value™ is ₩9,890.20, compared to a current price of ₩3,310.00 — trading 66.5% below its estimated fair value. The current EBIT is ₩-25,554 Mil. Humasis Co's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Humasis Co (XKRX:205470), the current EBIT is ₩-25,554 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Humasis Co (XKRX:205470) Overvalued in 2026?
Based on GuruFocus' analysis, Humasis Co stock appears to be undervalued.
The current stock price of ₩3,310.00 is trading 66.5% below its estimated GF Value™ of ₩9,890.20.
GuruFocus considers Humasis Co to be Possible Value Trap.
Key valuation signals for XKRX:205470:
EBIT: ₩-25,554 Mil
GF Value™: ₩9,890.20 vs. price of ₩3,310.00 (66.5% below fair value)
No single metric tells the full story. See the XKRX:205470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:205470 has been successfully added to your 
